Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C19H23N3O5.C4H4O4 |
| Molecular Weight | 862.8782 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C\C(O)=O.CN[C@@H](CCOC1=CC=C(C=C1)[N+]([O-])=O)C2=CC=C(OC(=O)N(C)C)C=C2.CN[C@@H](CCOC3=CC=C(C=C3)[N+]([O-])=O)C4=CC=C(OC(=O)N(C)C)C=C4
InChI
InChIKey=JOSUCKKYZJUIPW-SOBORHNCSA-N
InChI=1S/2C19H23N3O5.C4H4O4/c2*1-20-18(12-13-26-16-10-6-15(7-11-16)22(24)25)14-4-8-17(9-5-14)27-19(23)21(2)3;5-3(6)1-2-4(7)8/h2*4-11,18,20H,12-13H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;;2-1+/t2*18-;/m00./s1
| Molecular Formula | C4H4O4 |
| Molecular Weight | 116.0722 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
| Molecular Formula | C19H23N3O5 |
| Molecular Weight | 373.403 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 16:59:03 GMT 2025
by
admin
on
Tue Apr 01 16:59:03 GMT 2025
|
| Record UNII |
6WJ4EP5PJ5
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
(4-((3S)-3-(4-(DIMETHYLCARBAMOYLOXY)PHENYL)-3-(METHYLAMINO)PROPOXY)PHENYL)AZINIC ACID FUMARIC ACID
Created by
admin on Tue Apr 01 16:59:03 GMT 2025 , Edited by admin on Tue Apr 01 16:59:03 GMT 2025
|
PRIMARY | |||
|
6WJ4EP5PJ5
Created by
admin on Tue Apr 01 16:59:03 GMT 2025 , Edited by admin on Tue Apr 01 16:59:03 GMT 2025
|
PRIMARY | |||
|
6918634
Created by
admin on Tue Apr 01 16:59:03 GMT 2025 , Edited by admin on Tue Apr 01 16:59:03 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
The compound was as effective as SERT inhibitors such as fluoxetine and fluvoxamine in a 5-hydroxytryptophan-enhancing test in mice. Spatial memory deficits in the two-platform task of a water maze in aged rats were ameliorated by RS-1259 as well as donepezil. Both RS-1259 and donepezil increased the awake episodes in the daytime electroencephalogram of rats. The efficacy of RS-1259 on the consciousness level, which reflects the whole activity in the brain, was almost the same as that of donepezil. These results suggest that both cholinergic and serotonergic systems are involved in maintaining brain arousal and that a dual inhibitor of AChE and SERT may be useful for the treatment of cognitive disorders associated with reduced brain activity such as in Alzheimer's disease.
|